Navigation Links
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/27/2009

hat a larger proportion of CPP-109-treated subjects than placebo-treated subjects are cocaine-free during their last two weeks of treatment (weeks 11 and 12). Additionally, Catalyst will be measuring a number of secondary endpoints based on reductions of cocaine use and craving. In January 2009, Catalyst completed enrollment for this trial, having enrolled 186 subjects at 11 addiction centers around the United States. Initial top-line results for the cocaine trial are expected at the end of the second quarter of 2009.

In June 2008, Catalyst initiated enrollment of subjects for its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial evaluating CPP-109 for the treatment of methamphetamine addiction using a trial protocol that is almost identical to the cocaine trial. On March 3, 2009, in order to conserve cash and to focus its development efforts on evaluating CPP-109 for the treatment of cocaine addiction, Catalyst announced that it had halted enrollment in the methamphetamine trial. Instead, the methamphetamine trial has been converted into a smaller proof-of-concept study with the 57 subjects who had already been enrolled. Initial results for the methamphetamine proof-of-concept study are expected in the third quarter of 2009.

About Catalyst Pharmaceutical Partners, Inc.

Catalyst Pharmaceutical Partners is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate is CPP-109, which is the C
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Using catalysts to stamp nanopatterns without ink
2. Experiments reveal unexpected activity of fuel cell catalysts
3. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
4. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
5. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
6. Controlling the size of nanoclusters: First step in making new catalysts
7. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
8. NIST and partners identify tiny gold clusters as top-notch catalysts
9. Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
10. Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
11. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors ... Plague.” In this time period, doctors did not know that ... to the death of vulnerable patients. In the same way, ... may be unwittingly transmitting herpes viruses to their patients. The ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... 21, 2009) A faster tool for cell programming and ... have won grand prizes of the 2009 Collegiate Inventors Competition, ... by the Abbott Fund, the non-profit foundation of the global ... Trademark Office (USPTO). Harris Wang, who invented a new ...
... Myriant Technologies LLC (Myriant), a privately-held, biotech developer ... of its Science Advisory Board and the appointment ... collectively will provide broad insight into all aspects ... biomass feedstocks into valuable chemicals. , (Logo: ...
... N.J. and WALTHAM, Mass., Oct. 21 BioWa, ... today that they have entered into an agreement ... POTELLIGENT(®) Technology platform for the development of antibody-dependent ... grants NKTT non-exclusive rights to research, develop, manufacture ...
Cached Biology Technology:Winners announced in 2009 Collegiate Inventors Competition 2Winners announced in 2009 Collegiate Inventors Competition 3Winners announced in 2009 Collegiate Inventors Competition 4Winners announced in 2009 Collegiate Inventors Competition 5Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 2Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 3BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 2BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 3
(Date:4/23/2014)... has transformed the energy landscape in the U.S., ... conflict among the energy industry, residents and agricultural ... add that degraded water quality is a potential ... article appears in the ACS journal Environmental ... and colleagues point out that a major criticism ...
(Date:4/23/2014)... the family of bacteria that causes whooping cough ... surprising findings about the bacteria,s origin and evolution. ... to control this respiratory disease, which kills 195,000 ... 343 strains of the Bordetella pertussis ... last 100 years illustrates how vaccination has shaped ...
(Date:4/23/2014)... quickly. It involves visual searching for clues to ... Similarly to humans, biological systems are sometimes under ... that need to be read quickly are usually ... easier it will be to read them quickly. ... Portugal) and Centre for Molecular and Structural Biomedicine ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Impact of whooping cough vaccination revealed 2Cell division speed influences gene architecture 2
... is nicknamed "yellowcake" for its color and powdered consistency. ... , The yellow monster surfaced on the Navajo Nation ... continued for the next several decades. In its aftermath ... and worries about environmental contamination among people who live ...
... one day precisely release drugs and vaccines inside the ... study, by researchers at Ghent University and the Universit? ... Jan. 9, 2006, print issue of the American Chemical ... other microcapsules, which release their drug cargo only when ...
... study is being published in an advance online version of ... XPB helicase from an archaea, a single cell organism similar ... strands of the nucleic acid double helix, an action that ... well as other cell processes. , "XPB was initially ...
Cached Biology News:Study may help slay 'Yellow Monster' 2Study may help slay 'Yellow Monster' 3Enzyme crystal structure reveals 'unexpected' genome repair functions 2